Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PHASE 1/2A DOSE ESCALATION, FINDING AND EXPANSION STUDY EVALUATING SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF-07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY

NCT04553133 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT04553133
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04553133 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PHASE 1/2A DOSE ESCALATION, FINDING AND EXPANSION STUDY EVALUATING SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF-07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 16, 2020
Completion date
December 31, 2026
Enrollment
157 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, ovarian cancer, small cell lung cancer